Immunome Advances Proprietary Antibody Against IL-38
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced that it advanced its …
Read More